Pulmonary Hypertension Clinical Trial
Official title:
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
NCT number | NCT01051960 |
Other study ID # | 10-000567 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | March 2009 |
Est. completion date | January 2011 |
Verified date | October 2020 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma
Status | Completed |
Enrollment | 12 |
Est. completion date | January 2011 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Systemic Sclerosis diagnosed by the American College of Rheumatology consensus statement including any of the following: - Limited - Diffuse - Sine Scleroderma 2. Patients must be willing and able to undergo right heart catheterization with lower extremity cycle ergometry 3. Mean pulmonary artery pressure (mPAP) > 30mmHg with exercise; PCWP = 15mmHg on RHC at rest 4. Men and women, ages 18 years of age or older 5. Standard adjunctive medications will be allowed concurrently in this study at the discretion of the treating pulmonologist and rheumatologist, including digoxin, diuretics, anticoagulants (e.g. warfarin), stable immunosuppression or other anti-fibrotic therapy for at least one month prior to enrollment Exclusion Criteria: 1. Resting PAH (mPAP > 25mmHg) on right heart catheterization 2. Other known causes of PAH including prior venous thromboembolism, HIV infection, chronic liver disease with portal hypertension, left ventricular systolic dysfunction (e.g. LVEF < 40%), and congenital causes of PAH 3. Severe hepatic disease precluding the use of ambrisentan (AST/ALT =3x ULN). 4. Women who are pregnant or breastfeeding. 5. Concurrent therapy with a prostanoid or prostanoid analogue, PDE5 inhibitors, or enrolled in another active clinical study. 6. Use of any prostacyclin or endothelial receptor antagonist (ERA) within 30 days before study entry. 7. Bed or wheel chair bound or a baseline 6-Minute Walk distance (6MWD) less than 150 meters. 8. Childbearing capable women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period. 9. New York Heart Association (NYHA) Classification: Class IV 10. Renal dysfunction (serum creatinine >2.5mg/dL). 11. Uncontrolled sleep apnea. |
Country | Name | City | State |
---|---|---|---|
United States | David Geffen School of Medicine, University of California, Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | Gilead Sciences |
United States,
Saggar R, Khanna D, Shapiro S, Furst DE, Maranian P, Clements P, Abtin F, Dua S, Belperio J, Saggar R. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 | We defined ePH (exercise PH) as an mPAP of 30 mmHg, PCWP of 18 mm Hg, and a transpulmonary gradient (TPG) of 15 mm Hg, where TPG equals mPAP minus PCWP. We defined ePVH (exercise pulmonary venous hypertension) as an mPAP of 30 mm Hg, PCWP of 18 mm Hg, and a TPG of 15 mm Hg. We defined eoPH (exercise out of proportion) as an mPAP of 30 mm Hg, PCWP of 18 mm Hg, and a TPG of 15 mm Hg (4). Our hypothesis was that SSc patients with normal exercise physiology and ePVH have a different patho-physiology compared to patients with pulmonary vascular disease (ePH and eoPH). | 24 weeks | |
Secondary | Change in Distance Walked in Six Minutes From Baseline to 24 Week | ATS guideline based assessment with known minimally clinically important difference | 24 weeks | |
Secondary | Quality of Life (QOL) Based on SF36 and HAQ-DI | Number of participants exceeding minimally important difference estimates on changes in quality of life as assessed by SF-36 (short form 36) quality of life index with mental and physical component scores, or by HAQ-DI (health assessment questionnaire disability index) limitations that may be related to musculoskeletal limitations | 24 weeks | |
Secondary | HAQ-DI (Health Assessment Questionnaire Disability Index) | Assessing limitations that may be related to musculoskeletal limitations, the HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items in which level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The 8 domain scores are averaged into a total HAQ-DI score ranging from 0 (no disability) to 3 (completely disabled). | 24 weeks | |
Secondary | St. George's Respiratory Questionnaire | To assess overall health, daily life, and perceived well-being in patients with underlying lung disease, the SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A |